Kezar Life Sciences, Inc.
KZR
$4.50
$0.102.27%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -- | -- | -- |
| Cost of Revenue | -23.29% | -7.14% | 17.36% | 79.75% | 198.40% |
| Gross Profit | 16.46% | -2.03% | -7.08% | -64.87% | -174.02% |
| SG&A Expenses | -11.86% | -9.04% | 20.05% | 25.43% | 31.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.58% | -7.61% | 18.03% | 39.62% | 57.72% |
| Operating Income | 15.30% | 0.94% | -10.27% | -30.84% | -47.88% |
| Income Before Tax | 17.80% | -9.10% | -19.43% | -36.17% | -49.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.80% | -9.10% | -19.43% | -36.17% | -49.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.80% | -9.10% | -19.43% | -36.17% | -49.28% |
| EBIT | 15.30% | 0.94% | -10.27% | -30.84% | -47.88% |
| EBITDA | 15.43% | 0.97% | -10.57% | -31.83% | -49.67% |
| EPS Basic | -1.56% | -8.52% | -18.68% | -31.82% | -38.28% |
| Normalized Basic EPS | -6.59% | 0.18% | -9.45% | -23.78% | -29.90% |
| EPS Diluted | -1.56% | -8.52% | -18.68% | -31.82% | -38.28% |
| Normalized Diluted EPS | -6.59% | 0.18% | -9.45% | -23.78% | -29.90% |
| Average Basic Shares Outstanding | 0.48% | 0.57% | 0.65% | 3.45% | 7.77% |
| Average Diluted Shares Outstanding | 0.48% | 0.57% | 0.65% | 3.45% | 7.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |